Dapprich Daniel C, Weenig Roger H, Rohlinger Audrey L, Weaver Amy L, Quan Katherine K Lim, Keeling James H, Walsh John S, Otley Clark C, Christenson Leslie J
Department of Dermatology, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Am Acad Dermatol. 2008 Sep;59(3):405-17. doi: 10.1016/j.jaad.2008.05.015. Epub 2008 Jun 16.
There is concern that the immunologic tumor malignant melanoma (MM) may have worse outcomes in immunosuppressed hosts than in the general population.
We sought to describe outcomes of MM in immunosuppressed solid organ transplant recipients and compare them with the general population.
We conducted a retrospective review of medical charts and pathology slides of cases of MM and solid organ transplantation between 1978 and 2007, with comparison of outcomes.
In all, 48 MMs were identified in 43 transplant recipients. No patient with MM before transplant receipt had melanoma recurrence, subsequent metastasis, or death caused by melanoma. Of patients with MM diagnosed after transplantation, metastases developed in 3 patients, and two patients died of melanoma.
Retrospective review and low number of cases are limitations.
Outcomes of MM in immunosuppressed transplant recipients appeared similar to those in prognostically matched nonimmunosuppressed hosts. The small number of cases limited statistical comparisons.
人们担心免疫性肿瘤恶性黑色素瘤（MM）在免疫抑制宿主中的预后可能比在普通人群中更差。
我们试图描述免疫抑制实体器官移植受者中MM的预后，并将其与普通人群进行比较。
我们对1978年至2007年间MM病例和实体器官移植的病历及病理切片进行了回顾性研究，并比较了预后情况。
共在43名移植受者中发现了48例MM。移植前患有MM的患者均未出现黑色素瘤复发、随后的转移或因黑色素瘤导致的死亡。在移植后诊断出MM的患者中，有3例发生了转移，2例死于黑色素瘤。
回顾性研究和病例数量少是局限性所在。
免疫抑制移植受者中MM的预后似乎与预后匹配的非免疫抑制宿主相似。病例数量少限制了统计比较。
